Related Experiment Video
Updated: Jan 7, 2026
12:09
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
17
Breast Cancer Therapy by Small-Molecule Reactivation of Mutant p53
Simon H Slight1, Salman M Hyder1
1Department of Pathobiology and Integrative Biomedical Sciences, University of Missouri, Columbia, MO 65211, USA.
Current Oncology (Toronto, Ont.)
|December 24, 2025
Summary
Reactivating mutant p53 (mtp53) with small molecules like PRIMA-1 and APR-246 shows promise in fighting breast cancer, particularly triple-negative breast cancer (TNBC). These compounds restore wild-type p53 tumor suppressor activity, inhibiting tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- The p53 protein is a crucial tumor suppressor involved in DNA stability and apoptosis.
- Mutations in p53 are common in many cancers, including 30-40% of breast cancers and 70-80% of triple-negative breast cancer (TNBC).
- Mutant p53 (mtp53) accumulation drives tumor development, making its reactivation a potential therapeutic strategy.
Purpose of the Study:
- To investigate the potential of small molecule activators to restore the function of mtp53 in breast cancer.
- To evaluate the efficacy of PRIMA-1 and its analog APR-246 in preclinical models of breast cancer, including TNBC.
Main Methods:
- Utilized small molecules, PRIMA-1 and APR-246, to target and reactivate mtp53.
- Tested compound efficacy in hormone-dependent human breast cancer cells and TNBC cells.
- Assessed tumor growth inhibition using xenograft models in animals.
Main Results:
- PRIMA-1 demonstrated the ability to reactivate mtp53 in hormone-dependent breast cancer cells.
- PRIMA-1 effectively arrested tumor growth in a preclinical xenograft model.
- APR-246 successfully restored wild-type p53 tumor suppressor activity in TNBC cells.
Conclusions:
- Small molecule activators represent a promising approach to combatting breast cancer by restoring p53 function.
- Further research into compounds like PRIMA-1 and APR-246, including naturally occurring compounds, could lead to novel TNBC treatments.
- Clinical trials are exploring p53 reactivation as a cancer therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:23Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
01:31The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K